Close

Endologix (ELGX) Announces Presentation of Nellix EVAS System Post-Market Study Data in AAA Patients

Go back to Endologix (ELGX) Announces Presentation of Nellix EVAS System Post-Market Study Data in AAA Patients

Leerink Partners Cuts Price Target on Endologix (ELGX) to $8 Following Analyst Day

November 18, 2016 7:20 AM EST

Leerink Partners maintained a Market Perform rating on Endologix (NASDAQ: ELGX), and cut the price target to $8.00 (from $11.00), following the company's analyst day. The focus of the presentation was around Nellix. There was news on Wednesday that potential approval has been pushed out ~6 months. This comes following a request for additional info from the FDA. Management also updated 2016 revenue... More

JPMorgan Downgrades Endologix (ELGX) to Neutral

November 16, 2016 10:11 AM EST

JPMorgan downgraded Endologix (NASDAQ: ELGX) from Overweight to Neutral with a price target of $10.00 (from $14.00).

For an analyst ratings summary and ratings history on Endologix click here. For more ratings news on Endologix click here.

Shares of Endologix closed at $9.84 yesterday.

... More

Endologix (ELGX) will resume trading at 9:50am ET

November 16, 2016 9:22 AM EST

Endologix (NASDAQ: ELGX) will resume trading at 9:50am EST.

... More

Endologix (ELGX) Announces FDA Request for Follow-up Data on EVAS-FORWARD IDE Study of Nellix EVAS System

November 16, 2016 9:02 AM EST

Endologix, Inc. (Nasdaq: ELGX) announced that the U.S Food and Drug Administration (FDA) has requested the Company provide 2-year patient follow-up data from the EVAS-FORWARD IDE Study of the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). The Company expects these data to be available and submitted to the FDA in the second quarter of 2017, followed by a possible FDA advisory panel meeting by the end of 2017, and potential FDA PMA approval of Nellix in the second quarter of... More

Endologix (ELGX) trading halted with news pending

November 16, 2016 8:55 AM EST

Endologix (NASDAQ: ELGX) trading halted with news pending.

... More